MET and non-small cell lung carcinoma: In addition, there are other phase II ongoing clinical trials evaluating the effectiveness of crizotinib in advanced refractory NSCLC characterized by MET amplification and MET exon 14 skipping mutation and also in patients with NSCLC with ROS1 fusion (NCT02664935, NCT02465060, NCT04084717).